INTRODUCTION
Angiogenesis is critical to the growth, invasion, and metastasis of human tumors. Key to this process is the vascular endothelial cell (EC) 1 , which in health responds to a balance between pro-and antiangiogenic factors secreted by various cells to maintain blood vessel homeostasis.
This balance determines whether ECs become angiogenic in response to normal physiologic signals in processes as diverse as wound repair, the menstrual cycle, embryogenesis, and organogenesis 2, 3 . During carcinogenesis, tumors hijack angiogenesis by secreting proangiogenic factors in order to supply themselves with the oxygen and nutrients necessary for their continued growth, a transition known as the "angiogenic switch" 2, 3 . Because targeting angiogenesis has emerged as a promising avenue of treatment for malignancies 4 , understanding the transcriptional regulation of the angiogenic phenotype in ECs has become increasingly important.
Not surprisingly, given their diverse roles in development, homeobox genes are involved in the regulation of this transition between the resting and "activated," or "angiogenic,"
phenotype in ECs [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Proangiogenic homeobox genes [5] [6] [7] [8] 14, 20 and antiangiogenic homeobox genes have been described 12, 13, [15] [16] [17] [18] , as have differences in homeobox gene expression and function in
ECs from different vascular beds 17, 19, 21, 22 . The diverged homeodomain gene GAX (also known as MEOX2) is also expressed in ECs 12 , and previous work in our laboratory has implicated GAX in inhibiting nuclear factor-κB (NF-κB) signaling, as well as angiogenesis in ECs, both in vitro and in vivo 10, 13, 17 . Most recently, we have reported that GAX induces G 0 cell cycle arrest by activating the expression of p21 WAF1/CIP110 through its binding to AT-rich sequences in the p21 WAF1/CIP1 promoter and an enhancer site located approximately 13 kb upstream from the GAX start codon 10 .
Given its postulated role in regulating EC phenotype during angiogenesis, GAX represents a potentially important molecular target for the antiangiogenic therapy of cancer.
Consequently we wished to elucidate further how its expression is regulated in vascular ECs.
Noting its long 3'-untranslated region (3'-UTR), we hypothesized that GAX expression is likely to be regulated, at least in part, by microRNAs. MicroRNAs are short, single-stranded RNAs transcribed from noncoding genes, which after entry into the RNA interference pathway and maturation into ~22 base sequences bind to identical or similar sequences in the 3'-untranslated regions of genes, resulting in inhibition of translation or cleavage of the mRNA target [23] [24] [25] [26] , including specific HOX genes 27 . Although there is as yet little known about the role of specific microRNAs in regulating angiogenesis, there is evidence implicating overall microRNA levels 28, 29 and at least one specific microRNA 30 in regulating angiogenesis.
In order to test our hypothesis, we performed an in silico search for microRNA binding sites in the GAX 3'-UTR and identified consensus binding sites for multiple candidate microRNAs, of which only one (miR-130a) was expressed in proliferating ECs. Here we report that miR-130a is largely responsible for the downregulation of GAX expression due to mitogens and proangiogenic factors and antagonizes the antiangiogenic activity of GAX. Similar, but less potent, effects were observed for the antiangiogenic homeobox gene HOXA5 18 , which contains one miR-130a consensus sequence. We thus propose that miR-130a activity is related, at least in part, to its ability to downregulate the expression of two key antiangiogenic homeobox genes and that it is either a positive regulator of or permissive factor for the angiogenic phenotype in ECs.
We further suggest that miR-130a may represent a promising target for the antiangiogenic therapy of cancer.
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MATERIALS AND METHODS

Cells and cell culture
Human umbilical vein endothelial cells (HUVECs) and EGM-2 medium were obtained from BioWhittaker (Walkersville, MD), and HUVECs were cultured according to the manufacturer's instructions and as reported previously 10, 13, 17 .
Plasmid constructs
The construction of the Flag-tagged GAX expression vector (pcDNA3.1-GAX) has been described before 10 . The HOXA5 18 coding region containing the 3'-UTR and its miR-130a binding site was amplified by PCR, and inserted into the pcDNA3.1 expression vector with a Flag tag at the N-terminal end (pcDNA3.1-HOXA5). Also, a fragment containing miR-130a was cloned by PCR (sense: 5'-GGA ATT GCA ATG CTG AGG AG-3'; antisense: 5'GCC GTT TTC TTT GAG GAC TG-3') and inserted into pcDNA3.1 to produce pcDNA3.1-miR-130a.
To test their function, a 280 bp fragment containing the miR-130a targeting sites in the human GAX 3'-UTR 31 was isolated from HUVEC total DNA by PCR, and appended to the 3' end of the GAX cDNA after its stop codon, and this fusion inserted into pcDNA3.1 to produce pcDNA3.1-GAX-3'-UTR. This same 280 bp fragment of the GAX 3'-UTR containing the miR130a target sequence was also cloned into the psiCHECK™2 dual Luciferase reporter plasmid (Promega, Madison, WI) at the 3' end of the coding sequence of Renilla reniformis Luciferase to produce psiCHECK™2-GAX-3'-UTR. Finally, the GAX promoter (898 bp) was isolated from
HUVECs by PCR and cloned upstream of Luciferase in the pGL3 vector to produce pGAXLuciferase. All plasmid inserts were sequenced completely and microRNA and protein expression verified by Northern and Western blots, respectively.
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Northern blots
Total RNA was isolated from cells using Trizol (Invitrogen, Carlsbad, CA), following a modification of the manufacturer's protocol previously described 13, 32, 33 , after which 40 μg of each sample were separated using 8 M urea/15% denaturing polyacrylamide gel electrophoresis (PAGE), transferred to nylon membranes (Ambion, Foster City, CA), cross-linked with UV light, and baked in a vacuum at 80 °C for 1 hour. Probes (Table 1) were end-labeled with γ-32 P-ATP (300 Ci/mmol) using T4 polynucleotide kinase, and labeled probes were purified on a Sephadex G-25 column (Amersham, Buckinghamshire, UK). Blots were prehybridized in UltraHyb Oligo (Ambion, Austin, TX) and then hybridized at 42º C. Membranes were washed twice with 2x SSC/0.5% SDS at 42° C for 30 minutes and exposed at -80º C to Kodak BioMax MR film using an intensifying screen. The sequence of the U6 probe was 5'-GCA GGG GCC ATG CTA ATC TTC TCT GTA T-3'.
Western blots
Protein was isolated from cells for Western blot as previously described 10, 17 10, 17 . In general, a 1 μl:1 μg ratio of transfection reagent to DNA was used, and cells were exposed to reagent-DNA complexes for 1-3 hours, depending upon the experiment, after which they were incubated 16-24 hours and then harvested for RNA or protein isolation. Transfection efficiency was measured using a pcDNA3.1 construct expressing green fluorescence protein (pcDNA3.1-GFP) and found to be between 30% and 40%.
Also, a 2'-O-methyl-modified oligo-RNA inhibitor of miR-130a was designed according vector was used to equalize the total DNA amount as appropriate to the experiment. Cells were incubated in regular culture medium overnight, after which they were placed in medium containing 0.1%FBS, 2%, or 10% FBS for 6 hrs and then harvested for Luciferase assay.
Dual Luciferase reporter assays
Luciferase reporter assays were performed using the psiCHECK™2-GAX-3'-UTR vector.
Cells were grown to approximately 80% confluence in 6-well plates and cotransfected with psiCHECK™2-GAX-3'-UTR or psiCHECK™2 empty vector plus 0.5 μg pcDNA3.1-miR-130a
as described above and previously 10 . Cells were incubated with transfection reagent/DNA complex for three hours, and then refreshed with fresh EBM and supplements (Cambrex 7 only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From Corporation, East Rutherford, NJ) containing 2% FBS or 0.1% FBS overnight. In a separate set of experiments, cells were incubated for 12 hours after transfection with 10 ng/ml vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and or tumor necrosis factor-α (TNF-α). Firefly and Renilla Luciferase activities were evaluated using the DualLuciferase Reporter Assay system (Promega, Madison, WI), and Renilla Luciferase activity normalized to firefly Luciferase activity. In the case of Luciferase assays using pGAXLuciferase, Luciferase activity was normalized to Renilla Luciferase activity according to previously reported protocols 10 .
Quantitative reverse transcriptase real time polymerase chain reaction (QRT-PCR)
RNA (1.0 μg) used to synthesize cDNA using the iScrit cDNA Synthesis kit (Bio-Rad, Hercules, CA). cDNA was then subjected to quantitative real time PCR utilizing TaqMan probes to determine the GAX mRNA level as previously described 17 was used to analyze the data and determine the threshold count (C t ). PCR cycles started with an initial 1.5 minute denaturation step at 95° C, followed by 30 to 40 cycles of denaturation at 95° C for 10 seconds; annealing at 56° for 20 seconds; and extension at 72° C for 30 seconds. Each sample was run in triplicate and C t determined for the target gene. GAX levels were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using the ΔΔCt method, as described previously 10, 33, [36] [37] [38] [39] [40] .
Migration and tube formation assays.
Migration and tube formation assays were carried out as described previously 13, 41 . low-powered field (50X) for each well was determined for at least five fields by an observer blinded to experimental groups according to protocols used previously in our laboratory 13, 17 . This methodology is adequate to detect changes in tube formation of approximately 25% reliably.
Finally, both migration and tube formation assays were carried out in the presence of 0 to 100 nM miR-130a inhibitor.
Immunofluorescence
HUVECs growing on cover slides were co-transfected with pcDNA3.1-GAX-3'-UTR, plus either pcDNA3.1-miR-130a or control vector as described above (ratios described for each experiment), and then incubated in fresh culture medium overnight containing either varying concentrations of FBS. Cells were fixed with 4% PFA for 10 min at room temperature, followed by incubation in methanol for 20 min. on ice. After three washes, the cells were permeabilized with 1% Triton X-100-PBS, and further blocked with 5% goat serum. Immunostaining was performed using monoclonal antibody to Flag tag (Sigma, MO) to identify exogenous protein using Alexa Fluor488-labeled goat anti-mouse IgG (Molecular Probes, Invitrogen, Carlesbad,
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From CA) as the secondary antibody. Cell nuclei were stained with TO-PRO-3 Iodide (Molecular Probes, Invitrogen, Carlesbad, CA), and fluorescence was analyzed using a Nikon C1 Digital Eclipse confocal microscope system. Images were acquired under the same conditions for each experiment, and no digital manipulation of images was performed other than cropping.
Cell cycle analysis
Flow cytometry and cell cycle analysis were performed using HUVECs as previously described 42 . In brief, HUVECs rendered quiescent by incubation in 0.1% FBS-containing medium for 24 hours were cotransfected with pcDNA3.1-GAX and pcDNA3.1-miR-130a, incubated 24 hours in normal growth medium supplemented with 10 ng/ml VEGF. Cells were then harvested, fixed with -20°C cold absolute ethanol for 1 hour at 4°C, washed twice, and then incubated with 1 ml of 50 µg/ml propidium iodide (PI) staining solution before cell cycle analysis on a Beckman-Coulter Cytomics FC500 flow cytometer (Fullerton, CA).
Statistics and data analysis
Samples for QRT-PCR were always run in triplicate. All experiments were repeated at least a total of three times. Statistical significance was determined either by one-way ANOVA or the unpaired Student's t-test as appropriate, depending on the number of experimental groups analyzed.
RESULTS
The GAX 3'-UTR contains consensus sequences for miR-130a
Given the length of the GAX 3'-UTR (1,153 nucleotides) 32 , we considered it likely that sequences in the GAX 3'-UTR might represent a point of regulation of GAX expression by microRNAs. In order to estimate the contribution of transcriptional regulation through the GAX promoter to GAX expression, we transfected HUVECs with a pGAX-Luciferase, a promoter construct containing the full length GAX promoter linked to Luciferase and then incubated the 10 only.
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Next, we performed an in silico search for microRNA binding sites over the full length GAX cDNA sequence containing the 3'-UTR using the PicTar algorithm (http://pictar.bio.nyu.edu 43, 44 ) . Using this strategy, we identified 11 microRNA consensus sequences: miR-30a, miR-30b, miR-30c, miR-30e, miR-130a, miR-130b, miR-148a, miR-148b, miR-152, miR-206, and miR-301. Next, we subjected RNA from both rapidly growing and serum-starved HUVECs to Northern blot for these microRNAs (probe sequences in Table 1 ), detecting expression of only one of these microRNAs, miR-130a ( Figure 1B ). Moreover, miR130a expression was undetectable in quiescent HUVECs and strongly upregulated after exposure to FBS (Figure 1 , B and C). We further noted that there is a 280 bp sequence in the GAX 3'-untranslated region beginning at nucleotide 1594 (417 bases beyond the GAX stop codon), that contains two consensus sequences for miR-130a ( Figure 1D ). Given the presence of two miR130a consensus sequences in the GAX 3'-UTR and our observation that not only is miR-130a the only microRNA of these that is detectable in ECs by Northern blot but that it is upregulated by exposure to mitogens, we initially conclude that it is likely that it is miR-130a that contributes to the rapid downregulation of GAX expression that occurs in HUVECs in response to mitogenic stimuli.
miR-130a expression confers serum-responsiveness to a reporter gene
Next, to determine if these two miR-130a sequences in the GAX 3'-UTR contribute to the rapid downregulation of GAX expression, the 280 bp segment of the GAX 3'-UTR containing them was cloned into the psiCHECK™2 at the 3' end of the Renilla Luciferase gene ( Figure   2A ). Quiescent HUVECs were transfected with either psiCHECK™2 empty vector or 11 only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From psiCHECK™2-GAX-3'-UTR, after which they were exposed to either serum, proangiogenic factors (VEGF, bFGF, at 10 ng/ml each), or proinflammatory factors (10 ng/ml TNF-α) and incubated overnight. Cells were then harvested for dual Luciferase assay as described in Materials and Methods, with Luciferase activities in cells transduced with psiCHECK™2-GAX-3'-UTR were normalized to those of corresponding HUVECs transduced with empty vector to correct for transfection-related nonspecific changes in Luciferase activity. Exposure to FBS, VEGF, bFGF, and TNF-α all resulted in decreased Luciferase activity in HUVECs transfected with psiCHECK™2-GAX-3'-UTR ( Figure 2B ). Finally, we cotransfected HUVECs in serumcontaining media with psiCHECK™2-GAX-3'-UTR or psiCHECK™2 empty vector and varying concentrations of miR-130a inhibitor, using HUVECs in low serum medium as a control and observed that inhibition of miR-130a blocked the decrease in Luciferase activity due to exposure to serum ( Figure 2C ). From these data, we conclude that the 280 bp sequence in the GAX 3'-UTR containing the miR-130a consensus binding sites confers mitogen-responsive inhibition of expression to a reporter construct in HUVECs.
miR-130a binding sites in the GAX 3'-UTR mediate serum-induced downregulation
Quiescent HUVECs incubated for 16-18 hours in low serum medium (0.1% FBS) were exposed to either 0.1% (low serum medium, or LSM), 2%, or 10% FBS, incubated overnight, and then harvested for total RNA and protein. GAX message was then measured by QRT-PCR, and it was observed that FBS downregulated endogenous GAX expression in a dose-dependent fashion, as did conditioned media from the breast cancer cell line MCF7 ( Figure 3A) . A similar downregulation of GAX protein by serum was observed using Western blot ( Figure 3B ). 
quiescent by incubation in 0.1% FBS overnight were transduced with either pcDNA3.1-GAX or pcDNA3.1-GAX-3'-UTR and then incubated overnight in varying serum concentrations before plasmid-dependent GAX expression was measured. In order to measure only the transduced GAX and verify that the transduced GAX was localizing appropriately to the nucleus, we first chose to study GAX expression in HUVECs by immunofluorescence using anti-Flag antibody. Strikingly, downregulation of exogenous GAX expression in response to serum was greatly attenuated if only the coding sequence was used. However, adding back the consensus miR-130a sequences to the 3' end of the GAX coding sequence restored this downregulation due to serum ( Figure 3C ). Similar results were obtained in HUVECs treated identically and then subjected to Western blot with anti-Flag antibody ( Figure 3D ). From this we conclude that the miR-130a consensus binding sequences in the GAX 3'-UTR mediate the downregulation of GAX by mitogens and proangiogenic factors.
miR-130a downregulates endogenous GAX expression in HUVECs
Next, we directly tested whether miR-130a regulates endogenous GAX expression.
HUVECs were transfected with either pcDNA-3.1-miR-130a or empty vector, incubated overnight in 0.1% FBS to induce quiescence and maximal GAX expression, after which total RNA and protein were harvested for analysis. By both QRT-PCR ( Figure 4A (Figure 4, C and D) . Finally, cotransfecting with a 2'-O-methylmodified oligo-RNA miR-130a inhibitor more than reversed the downregulation of endogenous GAX expression due to serum ( Figure 4E ). We conclude from these experiments that miR-130a
regulates GAX expression through its consensus sequences in the 3'-UTR of the GAX gene.
miR-130a antagonizes the antiangiogenic activity of GAX
Next, we tested whether miR-130a expression plays a functional role in ECs. We therefore asked whether driving miR-130a expression can antagonize the known activities of GAX, specifically its ability to induce cell cycle arrest 10 and to inhibit EC tube formation on reconstituted basement membrane 10, 13 . Because EC proliferation in response to proangiogenic signals is a critical early step in angiogenesis, we first examined whether miR-130a can antagonize cell cycle inhibition by GAX. Quiescent HUVECs were cotransfected with pcDNA-3.1-miR-130a plus either pcDNA3.1-GAX or pcDNA3.1-GAX-3'-UTR, exposed to 10% FBS for 24 hours, and then harvested for flow cytometry to determine cell cycle distribution. miR-130a
clearly antagonizes the ability of GAX to induce G 0 cell cycle arrest in a manner consistent with targeting the miR-130a consensus sequences in the GAX 3'-UTR ( Figure 5A ). Next, we measured whether miR-130a can antagonize the ability of GAX to inhibit HUVEC migration towards serum and tube formation on reconstituted basement membrane as described in Materials and Methods. As with inhibition of cell cycle progression, miR-130a also antagonized inhibition of migration ( Figure 5C ) and tube formation ( Figure 5D ) due to GAX. In both cases, the ability of miR-130a to antagonize GAX activity depended upon the presence of the two miR130a consensus sites in its 3'-UTR. Finally, we repeated the migration and tube formation experiments but added 100 nM miR-130a inhibitor during the transfection. miR-130a inhibitor reversed antagonism of GAX activity by miR-130a ( Figure 5 , E and F).
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Antiangiogenic homeobox gene HOXA5 has an miR-130a binding site in its 3'-UTR and is also regulated by miR-130a
In order to elucidate further whether miR-130a regulates other homeobox genes involved in regulating EC phenotype during angiogenesis, we performed an in silico search for other possible downstream targets and found over 400 candidates spanning nearly all gene functions, including transcription factors, genes involved in metabolism, and structural proteins. Of interest, we identified another antiangiogenic homeobox gene, HOXA5 18 , as a potential downstream target. Of note, HOXA5 upregulates p53 expression in breast cancer cells 45 and downregulates the expression of several genes involved in angiogenesis, including VEGFR2, ephrin A1, HIF-1α, and COX-2 18 . Examining the sequence of the HOXA5 cDNA for miR-130a binding sites, we found a consensus sequence 356 bp beyond the stop codon 46 . Consequently, we wished to learn whether miR-130a also regulates HOXA5 expression in ECs. As in the case of GAX, we observed significant downregulation of HOXA5 expression in response to incubation in medium supplemented with a relatively modestly increased serum concentration ( Figure 6A ). We also observed that miR-130a downregulated HOXA5 expression, but not as strongly as it did GAX ( Figure 6 , B and C).
miR-130a antagonizes the antiangiogenic activity of HOXA5
Finally, we wished to determine whether miR-130a could antagonize the antiangiogenic activity of HOXA5, as it can for GAX. The antiangiogenic activity of HOXA5 was somewhat weaker than that of GAX in this assay ( Figure 7) . Nonetheless, miR-130a antagonized HOXA5 activity, although the antagonism seemed less pronounced than what was observed for GAX.
This weaker effect of miR-130a on HOXA5 expression may be due to the presence of only one miR-130a consensus sequence in HOXA5 compared to the two in GAX.
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DISCUSSION
Cancer is an angiogenesis-dependent disease, which is why targeting tumor angiogenesis is of considerable interest as a therapeutic strategy. Key to this process is the cell that responds to these tumor-secreted factors, the vascular endothelial cell (EC) 47 . When stimulated by angiogenic factors, an EC undergoes distinctive phenotypic changes, becoming capable of invading the basement membrane, migrating towards the angiogenic signal, proliferating, forming new tubes, and ultimately secreting factors to attract pericytes to form mature blood vessels 1 .
We have been interested in the role of homeobox genes in regulating this phenotypic conversion. Specifically, we have concentrated on the role of the homeobox gene GAX (MEOX2), which has many properties suggestive of a role as a major, if not master, regulator of EC phenotype in response to pro-and anti-angiogenic signals. GAX is expressed in both vascular smooth muscle cells and ECs, and, consistent with a role inhibiting cell growth and activation,
GAX is expressed at its highest level in quiescent ECs and is rapidly downregulated when ECs are exposed to mitogens, proangiogenic factors, or pro-inflammatory factors. Moreover, GAX expression induces G 0 cell cycle arrest through p53-independent upregulation of p21 WAF1/CIP1 expression 10, 42 and downregulates the activity of NF-κB, resulting in the downregulation of its downstream targets 17 . In both in vitro and in vivo models in the peripheral vasculature, GAX expression inhibits angiogenesis 13, 17 . However, because GAX itself is antiangiogenic and a transcription factor, as a practical matter targeting it therapeutically is likely to be difficult. If, on the other hand, it were possible to target factors that downregulate GAX, such as microRNAs, this could represent a more practical strategy to keep the expression level of GAX high in the tumor vasculature by blocking its response to proangiogenic factors. Consistent with this observation, changes in microRNA expression profiles in response to angiogenesis have been reported 30 , as has at least one individual microRNA (miR-221/222) whose expression results in a profound effect on EC phenotype and angiogenesis 30 .
Our results suggest that at least one other microRNA (miR-130a) may be important in the regulation of EC conversion to the angiogenic phenotype. Very little is known about the function of this particular microRNA, but it does appear to be widely expressed in diverse cell types 54 .
During megakaryocyte development, it has been suggested that miR-130a targets MAFB, a transcription factor that is upregulated during megakaryocytic differentiation and induces the GPIIb gene 55 . In ECs, miR-130a expression is upregulated by mitogens and proangiogenic factors ( Figure 1A and not shown) in a manner that is reciprocal to that of GAX, which is rapidly downregulated by these factors 32 . Moreover, miR-130a downregulates GAX expression itself even in low serum, when GAX expression is normally at its highest (Figure 4) , and functionally 17 only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From antagonizes the antiangiogenic activity of GAX in vitro ( Figure 5 ). The ability of miR-130a to antagonize the antiangiogenic activity of GAX in these experiments is even more striking, given that our transfection protocol generally resulted in approximately 30-40% transfection efficiency (data not shown). Moreover, miR-130a is also able to downregulate the expression of at least one other antiangiogenic homeobox gene, HOXA5, and antagonize its function in ECs as well.
Although it does not appear to increase angiogenesis in vitro by itself, miR-130a does appear to downregulate the expression of factors, such as GAX and HOXA5, that keep ECs in their resting state, and our results suggest it as an important regulator of EC phenotype. We thus speculate that miR-130a may play a permissive role during angiogenesis by downregulating cellular "brakes" that keep ECs in a resting or non-angiogenic state, although we cannot rule out the possibility that miR-130a may indeed be proangiogenic and the limitations of our in vitro assays prevented us from detecting this activity.
We must also note that there are other microRNA consensus sites in the GAX 3'-UTR, including sites for miR-148/152, miR-1/206, and miR-409. However, most of these sites are also within the 280 bp segment of the GAX 3'-UTR, and we were unable to detect the expression of any of these other than miR-130a in our Northern blot screen ( Figure 1A ). Although we cannot entirely rule out the possibility that these micro-RNAs are also involved in the downregulation of GAX expression in response to serum or pro-angiogenic factors, given our results this seems an unlikely possibility. With that caveat in mind, it is tempting to envision a model in which different microRNAs or sets of microRNAs modulate GAX expression in response to different mitogens, proangiogenic factors, or pro-inflammatory factors in different vascular cell types in which GAX is expressed. Given the manner in which miRNA-130a downregulates both GAX and HOXA5, as well as functionally antagonizing their activities with respect to angiogenesis, we 18 only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From consider it likely that miR-130a is an important, if not the most important, regulator of GAX expression, and, to a lesser extent, HOXA5 expression. Such a result is not without precedent, as several homeobox genes have now been shown to be regulated by microRNAs. For example, miR-181 has been shown to target HOXA11 during myoblast differentiation 56 , and miR-196 directs the cleavage of HOXB8 27 .
In conclusion, our results suggest that microRNA sequences, specifically miR-130a, are important regulatory sequences in the GAX 3'-UTR that control the downregulation of GAX and HOXA5 expression in response to mitogens, proangiogenic factors, and pro-inflammatory factors.
Given that GAX appears to function to keep ECs in the resting, quiescent state, and that its downregulation occurs rapidly upon stimulation with mitogens, suggesting that its downregulation is a necessary precondition for ECs to reenter the cell cycle and become angiogenic, it is possible that miR-130a might represent a promising molecular target for the antiangiogenic therapy of cancer.
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For For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From overnight were transfected with empty vector or pcDNA-3.1-miR-130a and either pcDNA3.1-GAX or pcDNA3.1-GAX-3'-UTR as for the tube formation experiment and exposed to 10% FBS for 24 hours, after which cells were harvested, stained with propidium iodide, and subjected to flow cytometry to determine cell cycle distribution. By definition the change in the G 0 /G 1 fraction for the empty vector control is 0, and the G 0 /G 1 fraction for the vector control was 0.38 in the experiment displayed. Statistical significance was determined by one-way ANOVA, and both the miR-130a and GAX-3'-UTR + miR-130a groups showed a statistically significant (p < 0.01) change from the others. B. miR-130a antagonizes the anti-migration activity of GAX.
HUVECs were cotransfected with either pcDNA3.1-GAX-3'-UTR or pcDNA3.1-GAX plus either pcDNA3.1-miR130a or pcDNA3.1 control empty vector as described above and plated eighteen hours later onto 8.0 µm pore size polycarbonate membranes in 24-well plates and allowed to attach, after which migration assays were carried out as described in Materials and Methods.
Cells were counted in five high powered fields (hpf) per well (*p < 0.01 compared to empty vector control). C. miR-130a antagonizes the antiangiogenic activity of GAX. HUVECs were cotransfected with either empty vector or pcDNA3.1-miR-130a and pcDNA3.1-GAX-3'-UTR or pcDNA3.1-GAX and then incubated overnight, after which tube formation assays were carried out. The ratio of cotransfection was 2:1 miR-130a:GAX expression construct. Tube counts were 
